Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo
- 26 July 2006
- journal article
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 4 (8), 1707-1717
- https://doi.org/10.1111/j.1538-7836.2006.02025.x
Abstract
No abstract availableKeywords
This publication has 61 references indexed in Scilit:
- Attack of the acronyms: TTP, VWF, ADAMTS-13 and SELDI-TOF-MSJournal of Thrombosis and Haemostasis, 2006
- Binding of ADAMTS13 to von Willebrand FactorJournal of Biological Chemistry, 2005
- The spacer domain of ADAMTS13 contains a major binding site for antibodies in patients with thrombotic thrombocytopenic purpuraThrombosis and Haemostasis, 2005
- Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpuraBlood, 2004
- Thrombotic microangiopathy after allogeneic bone marrow transplantation: a pathologic abnormality associated with diverse clinical syndromesBone Marrow Transplantation, 2004
- An enzyme immunoassay of ADAMTS13 distinguishes patients with thrombotic thrombocytopenic purpura from normal individuals and carriers of ADAMTS13 mutationsThrombosis and Haemostasis, 2004
- Nonneutralizing IgM and IgG antibodies to von Willebrand factor–cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpuraBlood, 2003
- von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndromeBlood, 2002
- Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving proteaseBest Practice & Research Clinical Haematology, 2001
- Thrombotic thrombocytopenic purpura: outcome in 24 patients with renal impairment treated with plasma exchangeTransfusion, 1992